RxDoctor Payments Data

Matthew Drew, MD

Gastroenterology · Colorado Springs, CONPI 1841565058

Payments from drug & device makers

$4,323in general payments, 2019–2025

Across 55 payments — averaging $78.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • AbbVie$352
  • Johnson & Johnson$310
  • Pfizer$114
  • Bristol Myers Squibb$95
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$53
  • plus $172 from 7 others

What the payments were for

  • Consulting fees$2,88067%
  • Speaking & faculty fees$2756%
  • Food & beverage$1,16827%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,323 in reported general payments places this provider in the 60th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$107,334
Medicare patients
418
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab15$120,640
LinzessLinaclotide15$16,477
TrulancePlecanatide16$8,928
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag34$4,211
SutabSod Sulf/Pot Chloride/Mag Sulf23$3,765
Omeprazole117$2,125
Ursodiol11$1,999
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg56$1,433
Colestipol Hcl19$1,410
Budesonide DrBudesonide17$938
Pantoprazole Sodium44$589
Dicyclomine Hcl13$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$352$16,47715 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$53$8,92816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →